Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study

Chronic liver disease (CLD) is often complicated by severe thrombocytopenia (platelet count 50,000/µL at baseline: the proportions of patients who did not require platelet transfusion were 84-96%, which might be overestimated. The efficacy and safety of lusutrombopag were retrospectively investigat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC gastroenterology 2020-12, Vol.20 (1), p.427-427, Article 427
Hauptverfasser:	Nomoto, Hiroaki, Morimoto, Naoki, Miura, Kouichi, Watanabe, Shunji, Takaoka, Yoshinari, Maeda, Hiroshi, Sasaki, Takahiro, Koyashiki, Yohei, Kurata, Hidekazu, Numao, Norikatsu, Isoda, Norio, Yamamoto, Hironori
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood platelets Cinnamates Complications and side effects Drug therapy Hemorrhage Humans Liver cirrhosis Liver diseases Liver Diseases - complications Liver Diseases - therapy Multivariate analysis Patient outcomes Patients Platelet transfusion Platelets Receptors, Thrombopoietin Retrospective Studies Software Thiazoles Thrombocytopenia Thrombocytopenia - complications Thrombocytopenia - therapy Thrombopoietin Thrombopoietin receptor agonist Thrombosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Chronic liver disease (CLD) is often complicated by severe thrombocytopenia (platelet count 50,000/µL at baseline: the proportions of patients who did not require platelet transfusion were 84-96%, which might be overestimated. The efficacy and safety of lusutrombopag were retrospectively investigated in CLD patients with platelet count of 50,000/µL. However, lusutrombopag is effective and safe for CLD patients with a platelet count of
ISSN:	1471-230X 1471-230X
DOI:	10.1186/s12876-020-01573-9